| Trial ID: | L0439 |
| Source ID: | NCT06820567
|
| Associated Drug: |
Dapagliflozin (Dapa)
|
| Title: |
Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD
|
| Acronym: |
|
| Status: |
NOT_YET_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Diseases|Diabetes Type 2
|
| Interventions: |
DRUG: Dapagliflozin (DAPA)|DRUG: Placebo
|
| Outcome Measures: |
Primary: GFR in CKD patients, Measure eGFR using ckd epi equation to detect the effect of dapagliflozin in improvement of GFR in CKD patients, 6 months |
|
| Sponsor/Collaborators: |
Sponsor: Assiut University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
210
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2025-03-01
|
| Completion Date: |
2027-05-01
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-11
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT06820567
|
